Market Shaping for long-acting generic PrEP market



Global efforts to scale up new long-acting PrEP options such as the dapivirine vaginal ring (DVR) and long-acting cabotegravir (CAB-LA), are some of the tools being deployed to end AIDS by 2030. These efforts will remain fundamentally curtailed by limited supply and high costs, therefore, it is important to accelerate generic product development to establish healthy markets and enable equitable access to the holistic package of PrEP options. Beyond CAB-LA and DVR, there are also a number of additional new long-acting technologies in the product development pipeline. Currently, there are several access barriers that need to be addressed in order to establish long-acting PrEP healthy markets (i.e., markets that ensure quality, availability, supply security, and affordability, among other factors).

The project coordinates the execution of supply-side interventions to accelerate long acting PrEP product generic development and scale up by reducing access barriers, facilitating accelerated access to quality-assured long-acting generics and building healthy markets in LMICs. This project will work to reduce these access barriers, facilitate accelerated access to quality-assured long-acting generics and build healthy markets for them in LMICs and globally. The project will also address complexities and considerations that need to be managed to support the development, manufacturing, regulatory filings, commercial terms, and roll out of generic long-acting products.


  • Prof Saiqa Mullick, Principal Investigator
  • Vusile Butler, Co-Principal Investigator

Latest Update

March 2024

For more about Market Shaping for long-acting generic PrEP market please email

Research and Policy Briefs

Market Shaping

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.